AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28234826 — intervention group
Group type: COMPARATOR
Intervention: Round silicone implant
Number of subjects: 75
Study 28234826 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anatomical and round implants
Number of subjects: 75
Study 26634569 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA; 3 mg)
Number of subjects: 40
Study 26634569 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (CTR)
Number of subjects: 40
Study 23461421 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 0
Study 23461421 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 0
Study 21150631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal clonidine 1 μg kg⁻¹ with 0.25% bupivacaine (0.75 ml kg⁻¹)
Number of subjects: 90
Study 21150631 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal clonidine 0.75 μg kg⁻¹ with 0.25% bupivacaine (0.75 ml kg⁻¹)
Number of subjects: 90
Study 21150631 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (0.75 ml kg⁻¹) alone
Number of subjects: 90
Study 18458907 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory stimulation with 5 cc of lemon juice
Number of subjects: 19
Study 16882326 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg b.i.d.), Amoxicillin (1 g b.i.d.), Esomeprazole (20 mg b.i.d.) for 10 days (group A(1) and A(2))
Number of subjects: 163
Study 16882326 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment with Levofloxacin, Amoxicillin, and Esomeprazole at the same dose and duration (group B(1) and B(2))
Number of subjects: 163
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: W-CPC
Number of subjects: 21
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-W
Number of subjects: 21
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-TP
Number of subjects: 21
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-CPC
Number of subjects: 21
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: W-TP
Number of subjects: 21
Study 12631184 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-W
Number of subjects: 21
Study 12631184 — intervention group
Group type: COMPARATOR
Intervention: W-W
Number of subjects: 21
Study 10960839 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 11811
Study 10960839 — intervention group
Group type: COMPARATOR
Intervention: DRE screening
Number of subjects: 11811
Study 8925110 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO incompatibility cases (26 cases)
Number of subjects: 61
Study 8925110 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloantibodies cases (35 cases)
Number of subjects: 61
Study 8925110 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up of all cases
Number of subjects: 61
Study 1616472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain subjects (musicians with upper limb pain)
Number of subjects: 28
Study 1616472 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls (musicians without upper limb pain)
Number of subjects: 28
Study 1616472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pain subjects and pain-free controls)
Number of subjects: 28
Study 6507309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (small dose)
Number of subjects: 13
Study 6507309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (large dose)
Number of subjects: 13
Study 6507309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (small dose)
Number of subjects: 13
Study 6507309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (large dose)
Number of subjects: 13
Study 6507309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31778451 — intervention group
Group type: EXPERIMENTAL
Intervention: Agroforestry systems with Schizolobium parahyba in Intercrop-I
Number of subjects: 7
Study 31778451 — intervention group
Group type: EXPERIMENTAL
Intervention: Agroforestry systems with Parapiptadenia rigida in Intercrop-I
Number of subjects: 7
Study 31778451 — intervention group
Group type: EXPERIMENTAL
Intervention: Agroforestry systems with non-deciduous trees (higher crown shading)
Number of subjects: 7
Study 31778451 — intervention group
Group type: COMPARATOR
Intervention: Wheat monoculture (no tree species present)
Number of subjects: 7
Study 31778451 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvest management techniques (with and without harvesting of the forage species)
Number of subjects: 7
Study 30103399 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component telemonitoring intervention (self-measurements of nutritional outcomes and physical activity, education, and follow-up by a nurse)
Number of subjects: 214
Study 30103399 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component telemonitoring intervention
Number of subjects: 214
Study 30103399 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 214
Study 26755091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 20
Study 26755091 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 20
Study 24717460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement < 7.1 hours
Number of subjects: 439
Study 24717460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 7.1 to < 17.6 hours
Number of subjects: 439
Study 24717460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 17.6 to < 46.0 hours
Number of subjects: 439
Study 24717460 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy commencement ≥ 46.0 hours
Number of subjects: 439
Study 21952978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg twice a day
Number of subjects: 384
Study 21952978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 384
Study 21952978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice a day
Number of subjects: 384
Study 21952978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg twice a day
Number of subjects: 384
Study 21952978 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 384
Study 21952978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 20200757 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOS concentrations
Number of subjects: 1400
Study 20200757 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA concentrations
Number of subjects: 1400
Study 20200757 — intervention group
Group type: COMPARATOR
Intervention: Control group (primiparous women)
Number of subjects: 1400
Study 17012266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 198
Study 17012266 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 198
Study 17012266 — intervention group
Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 198
Study 14624915 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040
Study 14624915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 10989239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine BMD greater than 1.20 g/cm(2) (or 2.5 S.D. above the mean)
Number of subjects: 150
Study 10989239 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 0.1 g/cm(2) increase in lumbar spine BMD
Number of subjects: 150
Study 10989239 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 0.1 g/cm(2) increase in femoral neck BMD
Number of subjects: 150
Study 10989239 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy in osteoporotic women
Number of subjects: 150
Study 9411906 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 85
Study 9411906 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 10 mg
Number of subjects: 85
Study 9411906 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 85
Study 9411906 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 100 mg
Number of subjects: 85
Study 1428304 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine (C) 10 mg
Number of subjects: 32
Study 1428304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine (C) 10 mg plus Ibuprofen (I) 600 mg
Number of subjects: 32
Study 3935458 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg i.v.)
Number of subjects: 10
Study 3935458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (25 mg i.v.)
Number of subjects: 10
Study 3935458 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg i.v.)
Number of subjects: 10
Study 3935458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg and 100 mg i.v.)
Number of subjects: 10
Study 3935458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31757206 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 50 mg
Number of subjects: 110
Study 31757206 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 110
Study 29134633 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1419 (inhaled TLR9 agonist)
Number of subjects: 0
Study 29134633 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 27035595 — intervention group
Group type: COMPARATOR
Intervention: Black coffee (175 ml)
Number of subjects: 32
Study 27035595 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with 20% milk (175 ml)
Number of subjects: 32
Study 27035595 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with 50% milk (175 ml)
Number of subjects: 32
Study 24472665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma stored at 1-6 °C for 5 days
Number of subjects: 30
Study 22359099 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-electrolyte solution (PEG)
Number of subjects: 116
Study 22359099 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 116
Study 22359099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 116
Study 21147688 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 5 mg daily for 4 weeks
Number of subjects: 43
Study 21147688 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZA) 4 mg I.V. once at study initiation
Number of subjects: 43
Study 17650211 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic milk (Lactobacillus acidophilus strain 74‐2, 10(7) CFU ml(‐1), Bifidobacterium lactis strain 420, 10(7) CFU ml(‐1), 2% inulin) consumed for 4 weeks at 500 ml day(‐1)
Number of subjects: 26
Study 17650211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2% skimmed milk) consumed for 4 weeks at 500 ml day(‐1)
Number of subjects: 26
Study 16510462 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 90
Study 16510462 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 90
Study 16510462 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery)
Number of subjects: 90
Study 16510462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (medical and surgical)
Number of subjects: 90
Study 14634938 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-injection axillary brachial plexus block (group A)
Number of subjects: 100
Study 14634938 — intervention group
Group type: COMPARATOR
Intervention: Humeral approach (group H)
Number of subjects: 100
Study 10783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 30510
Study 10783203 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase thrombolytic therapy
Number of subjects: 30510
Study 10783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (adjusted for age)
Number of subjects: 30510
Study 10783203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (adjusted for 17 characteristics)
Number of subjects: 30510
Study 8626832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 8626832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8626832 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH
Number of subjects: 0
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical assessment of resectability
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic methods for resectable tumours
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive values in resectable disease
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive values in unresectable disease
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Average macroscopic diameter of resectable tumours
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing resectability
Number of subjects: 472
Study 1426302 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical pancreatic surgery
Number of subjects: 472
Study 4044777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms/day estradiol infusion
Number of subjects: 5
Study 4044777 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms/day estradiol infusion
Number of subjects: 5
Study 4044777 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 micrograms/day estradiol infusion
Number of subjects: 5
Study 31848172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection followed by balloon dilatation
Number of subjects: 110
Study 31848172 — intervention group
Group type: COMPARATOR
Intervention: Dilatation only
Number of subjects: 110
Study 31848172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection
Number of subjects: 110
Study 29063390 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year treatment group (2YG, N = 112)
Number of subjects: 222
Study 29063390 — intervention group
Group type: COMPARATOR
Intervention: 3-or-more-year treatment group (3YG, N = 110)
Number of subjects: 222
Study 27002857 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian tuboplasty (BET) during planned surgery
Number of subjects: 100
Study 27002857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BET)
Number of subjects: 100
Study 24284387 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-12-week treadmill exercise program (target lactate 2.0±0.5 mmol l(‐1))
Number of subjects: 72
Study 24284387 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 72
Study 23158112 — intervention group
Group type: EXPERIMENTAL
Intervention: Group‐Mediated Cognitive Behavioral (GMCB) intervention
Number of subjects: 0
Study 23158112 — intervention group
Group type: COMPARATOR
Intervention: Health education control condition
Number of subjects: 0
Study 19851869 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality metaphorical pairings
Number of subjects: 0
Study 19851869 — intervention group
Group type: COMPARATOR
Intervention: Low quality metaphorical pairings
Number of subjects: 0
Study 19032235 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax
Number of subjects: 151
Study 19032235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 16118817 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide spray
Number of subjects: 0
Study 16118817 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine provision
Number of subjects: 0
Study 16118817 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 12014417 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 50
Study 12014417 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated lubricant (control)
Number of subjects: 50
Study 12014417 — intervention group
Group type: EXPERIMENTAL
Intervention: Anoscopy
Number of subjects: 50
Study 12014417 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy without anoscopy
Number of subjects: 50
Study 10418840 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinus toxin Type A (400 mouse units injected into calf muscles)
Number of subjects: 20
Study 10418840 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol (3 ml of 5% phenol for tibial nerve blockade)
Number of subjects: 20
Study 8847032 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole daily + 500mg Amoxicillin qid
Number of subjects: 73
Study 8847032 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole bid + 500mg Amoxicillin qid
Number of subjects: 73
Study 8847032 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole tid + 500mg Amoxicillin qid
Number of subjects: 73
Study 8847032 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg Omeprazole qid + 500mg Amoxicillin qid
Number of subjects: 73
Study 8847032 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 73
Study 8847032 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 73
Study 1962776 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-labeled monoclonal antibody
Number of subjects: 52
Study 1962776 — intervention group
Group type: COMPARATOR
Intervention: CT and histologic confirmation
Number of subjects: 52
Study 6106739 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic precipitator used during the night
Number of subjects: 10
Study 6106739 — intervention group
Group type: COMPARATOR
Intervention: Control period (no electrostatic precipitator)
Number of subjects: 10
Study 29746133 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation X2
Number of subjects: 4
Study 29746133 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation X1
Number of subjects: 4
Study 29746133 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation Y1
Number of subjects: 4
Study 29746133 — intervention group
Group type: COMPARATOR
Intervention: In vitro dissolution experiment
Number of subjects: 4
Study 28104073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation at dispersion areas
Number of subjects: 105
Study 28104073 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation approach (validation set)
Number of subjects: 105
Study 25800496 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 200
Study 25800496 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 200
Study 24062178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (5th dose)
Number of subjects: 57
Study 24062178 — intervention group
Group type: COMPARATOR
Intervention: Control group (MenB vaccine-naive participants receiving 4CMenB)
Number of subjects: 57
Study 21959035 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical orthosis training
Number of subjects: 12
Study 21959035 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 12
Study 18379855 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in patients with unstable angina pectoris (group I)
Number of subjects: 220
Study 18379855 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in patients with non-ST-elevation infarction (group II)
Number of subjects: 220
Study 18379855 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in patients with ST-elevation infarction (group III)
Number of subjects: 220
Study 18379855 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CABG in patients with ACS
Number of subjects: 220
Study 18379855 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from onset of symptoms to revascularization in STEMI group
Number of subjects: 220
Study 16855778 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic method
Number of subjects: 23
Study 16855778 — intervention group
Group type: COMPARATOR
Intervention: Transurethral method
Number of subjects: 23
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting beta2-agonists
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (anticholinergic)
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long-acting beta2-agonist and inhaled corticosteroid
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary oxygen therapy
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management programs
Number of subjects: 0
Study 14600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation
Number of subjects: 0
Study 10973647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization after IUI (group I)
Number of subjects: 116
Study 10973647 — intervention group
Group type: COMPARATOR
Intervention: 10 minutes of bed rest after IUI (group II)
Number of subjects: 116
Study 8977745 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day carbimazole
Number of subjects: 63
Study 8977745 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day carbimazole
Number of subjects: 63
Study 1334465 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with short AVD (100 ms)
Number of subjects: 13
Study 1334465 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with long AVD (150 ms)
Number of subjects: 13
Study 1334465 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 13
Study 6721539 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied technical fenvalerate
Number of subjects: 0
Study 6721539 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy‐ends fraction of fenvalerate
Number of subjects: 0
Study 6721539 — intervention group
Group type: COMPARATOR
Intervention: Ethyl alcohol (vehicle)
Number of subjects: 0